| Literature DB >> 24395385 |
Sakthivel Muniyan1, Yu-Wei Chou1, Te-Jung Tsai1,2, Paul Thomes1, Suresh Veeramani1, Benedict B Benigno3, L DeEtte Walker4, John F McDonald4, Shafiq A Khan5, Fen-Fen Lin1, Subodh M Lele6, Ming-Fong Lin1,7,8,9.
Abstract
p66Shc functions as a longevity protein in murine and exhibits oxidase activity in regulating diverse biological activities. In this study, we investigated the role of p66Shc protein in regulating ovarian cancer (OCa) cell proliferation. Among three cell lines examined, the slowest growing OVCAR-3 cells have the lowest level of p66Shc protein. Transient transfection with p66Shc cDNA expression vector in OVCAR-3 cells increases cell proliferation. Conversely, knock-down of p66Shc by shRNA in rapidly growing SKOV-3 cells results in decreased cell growth. In estrogen (E2)-treated CaOV-3 cells, elevated p66Shc protein level correlates with ROS level, ErbB-2 and ERK/MAPK activation, and cell proliferation. Further, the E2-stimulated proliferation of CaOV-3 cells was blocked by antioxidants and ErbB-2 inhibitor. Additionally, in E2-stimulated cells, the tartrate-sensitive, but not the tartrate-resistant, phosphatase activity decreases; concurrently, the tyrosine phosphorylation of ErbB-2 increases. Conversely, inhibition of phosphatase activity by L(+)-tartrate treatment increases p66Shc protein level, ErbB-2 tyrosine phosphorylation, ERK/MAPK activation, and cell growth. Further, inhibition of the ERK/MAPK pathway by PD98059 blocks E2-induced ERK/MAPK activation and cell proliferation in CaOV-3 cells. Moreover, immunohistochemical analyses showed that the p66Shc protein level was significantly higher in cancerous cells than in noncancerous cells in archival OCa tissues (n = 76; P = 0.00037). These data collectively indicate that p66Shc protein plays a critical role in up-regulating OCa progression.Entities:
Keywords: ErbB-2 signaling; ROS; estrogen; p66Shc; tyrosine phosphatase
Mesh:
Substances:
Year: 2014 PMID: 24395385 PMCID: PMC4117819 DOI: 10.1002/mc.22129
Source DB: PubMed Journal: Mol Carcinog ISSN: 0899-1987 Impact factor: 4.784